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placebo BID (n = 102). Treatment began within 28 d ys 
of diagnosis. Tumor response and safety were assessed; 
the primary endpoint was overall survival (OS). Patients 
who received ≥1 dose of treatment were included in the 
safety analysis. All randomized patients were included in 
the efficacy endpoint analyses. Patient characteristics were 
well balanced between treatment arms. Median OS was 
185  days for patients treated with WBRT plus placebo 
and 209 days for WBRT plus veliparib (50 or 200 mg). 
No statistically significant differences in OS, intracranial 
response rate, and time to clinical or radiographic progres-
sion between any of the treatment arms were noted. No 
differences were observed in adverse events (all grades) 
across treatment arms; nausea, fatigue, alopecia, and head-
ache were the most commonly reported. No new safety 
signals were identified for veliparib. A significant unmet 
need for therapies that improve the outcomes of patients 
with brain metastases from NSCLC remains.
Keywords Veliparib · PARP inhibitor ·  
Whole-brai  r diation therapy · Brain metastases ·  
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Introduction
Brain metastases are the most common intracranial malig-
nancy affecting up to 30 % of patients diagnosed with cancer 
with an estimated annual incidence of more than 200,000 
cases in the USA [1]. Approximately 7.4 % of patients with 
non-small cell lung cancer (NSCLC) will present with brain 
metastases at diagnosis; an additional 25–30 % w ll develop 
brain metastases over the course of their disease [2]. These 
patients have a very poor prognosis (median survival 
between 3 and 4.9 months) and an impaired quality of life 
Abstract Veliparib is a potent, orally bioavailable, poly 
(adenosine diphosphate-ribose) polymerase (PARP) inhibi-
tor that crosses the blood–brain barrier and has been shown 
to potentiate the effects of radiation in preclinical and arly 
clinical studies. This phase 2, randomized, global study 
evaluated the efficacy and safety of veliparib in combi-
nation with whole-brain radiation therapy (WBRT) in 
patients with brain metastases from non-small cell lung 
cancer (NSCLC). Three-hundred and seven patients with 
brain metastases from NSCLC were random ze  1:1:1 to 
WBRT (30  Gy in 10 fractions) plus 50 mg veliparib twice 
daily (BID; n = 103), 200 mg veliparib BID (n = 102), or 
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the preclinical and early clinical studies supported the ran-
domized phase 2 evaluation of combination therapy with 
veliparib and WBRT in patients with brain metastases from 
NSCLC. Two doses of veliparib were evaluated (50 and 
200 mg) based on the expected efficacious dose from the 
phase 0 study and the recommended phase 2 dose from the 
phase 1 study, respectively. The primary endpoint for the 
trial was OS. Given that OS is a difficult endpoint in this 
population due to the effects of non-cranial disease, addi-
tional endpoints were measured to look for potentiation of 
radiation on the local, intracranial disease. These endpoints 
included radiographic tumor progression, clinical progres-
sion, QoL, and neurocognitive abilities.
Methods
This global phase 2, randomized, double blinded, multi-
center study evaluated WBRT in combination with veliparib 
or placebo in patients with brain metastases from NSCLC. 
The study consisted of a treatment period, and a long-term 
follow-up period. During the long-term follow-up period, 
study visits for safety, radiographic response and neurologic 
assessments were performed monthly for 9 up to 24 months, 
and survival and post-treatment therapy data were collected 
at 2-monthly intervals for 6 months beginning at month 2 
and every 3 months afterwards for up to 36 months, or as
needed for more frequent data collection. The study objec-
tives were to evaluate the efficacy and safety of WBRT 
administered in combination with veliparib BID (50 or 
200 mg) versus placebo BID. The primary endpoint was 
OS. Secondary endpoints included best tumor response, 
time to intracranial radiographic progression, and time to 
clinical brain metastasis progression.
Eligible patients had cytologically or histologically 
confirmed NSCLC and brain metastases demonstrated via 
magnetic resonance imaging (MRI) brain scan. Total num-
ber of brain metastases was not a part of inclusion criteria. 
Patients had to be over the age of 18 years and be ligible 
for WBRT treatment (per investigator), with Karnofsky 
performance status (KPS) scores ≥70, and have adequate 
hematologic, renal, and hepatic function. Patients could 
not have been diagnosed with brain metastases >28 days
before commencing treatment or have received prior cra-
nial radiation or undergone resection for brain metastases. 
To exclude patients who might be more likely to die from 
systemic disease as opposed to neurologic disease, addi-
tional exclusion criteria included more than two sites of 
metastases from NSCLC (excluding the brain, bone, and 
thorax) and evidence of liver metastases. Due to the very 
poor outcomes for patients with leptomeningeal metastases 
and subarachnoid spread of the tumor, these patients were 
excluded.
(QoL) with significant neurologic, cognitive, and emotional 
impairment [3].
Whole-brain radiation therapy (WBRT) s the sta d rd 
of care for patients with brain metastases that are surgi-
cally unresectable or have multiple l sions [1]. Treat en  is 
associated with improvement in neurologic symptoms and 
decreased neurologic death [4]. In candidates suitable for 
resection or radiosurgery, the therapeutic value f WBRT is 
supported by level 1 evidence in terms of fur her reduction 
in intracranial failure [5–7]. However, treatment is likely 
associated with cognitive decline and the impact on survival 
remains controversial [8–10]. As a result, the optimal man-
agement of patients with brain metast ses is controversial, 
given the array of treatment options and strong opinions 
regarding the utilization of these options [11 ].
The combination of WBRT and agen s with radiosensi-
tizing properties has been evaluated to improve upon the 
results of WBRT alone [12 , 13]. Randomized, controlled 
trials have failed to demonstrate a categorical benefit in 
this setting for either local brain tumor control or ove ll
survival (OS) [14 ,15 ]. Therefore, there remains a signifi-
cant unmet medical need for patients with multiple brain 
metastases.
Poly (adenosine diphosphate-ribos ) polymerase (PARP) 
is a family of enzymes involved in a number of cellular pro-
cesses, including DNA replication, transcription, and cell 
death [16 ]. Increased PARP activity has b en observed in 
numerous cancers, and is thought to be one possibl  mecha-
nism of resistance to cell-death by DNA-damagi g hera-
peutics. There is evidence that the absence of PARP-1 and 
-2, which are both activated by DNA damage and facilitate 
DNA repair, results in hypersensitivity to ionizing radia-
tion [17]. Therefore, the inhibition of PARP-mediated DNA 
damage repair can help sensitize e ls to DNA-d maging 
agents.
Veliparib (ABT-888) is a potent, orally bioav ilable, 
PARP-1 and -2 inhibitor that has th  ability to ross the 
blood–brain barrier. In preclinical models, veliparib poten-
tiated the antitumor activity of fractionat d radiation [18 , 
19 ] and inhibited PARP levels in patient tu ors in a phas  0 
biopsy trial at doses as low as 25 mg [20]. A phase 1 study of 
veliparib in combination with WBRT was then initiated to 
understand the safety and tolerability in patients with brain 
metastases. The study included patients with brain metas a-
ses from a variety of tumor types, and escalated the d s  of 
veliparib from 10 to 300 mg. Veliparib was asso iat d with 
infrequent Grade 3 toxicities up o doses as high as 300 mg 
twice daily (BID); however, 200 mg BID was selected as 
the recommended phase 2 dose due to frequent Grade 2 nau-
sea events. In a cohort of 15 patients with brai  m tastas s 
from NSCLC, tumor responses (46 % versus 25–30 %) and 
median survival (10.5 months versus 3–4.5 months) were 
increased compared with historical ata [21 –24 ]. Thus, b th 
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and neurocognitive test battery) were performed monthly 
(30-day intervals) for 9 months, and every 3 months there-
after for up to 24 months.
Due to the potential of long-term sequelae from veliparib 
combined with WBRT, after 3 years of follow-up, patients 
who had not previously had clinical progression of disease 
were offered continued neurologic assessments until they 
experienced clinical brain metastases progression (with or 
without radiographic progression), or discontinued for any 
other reason (including death). During this time, study visits 
were performed every 3 months. Radiographic brain metas-
tases progression was assessed by the investigator at each 
study site and independently by a central imaging center. 
Radiographic response or progression was modeled after 
the Macdonald criteria [25] with response evaluation cri-
teria in solid tumors (RECIST) definitions of measurable 
lesions and non-target lesions [26 , 27].
The distribution of the primary endpoint OS was estimated 
for each treatment group using Kaplan–Meier methodology 
and compared between WBRT plus veliparib 50 mg BID and 
WBRT plus placebo BID, as well as between WBRT plus 
veliparib 200 mg BID and WBRT plus placebo BID treat-
ment groups using the log-rank test stratified by GPA score 
(≤2.5 versus >2.5). All other time-to-event endpoints (time 
to clinical brain metastases progression, time to intracranial 
radiographic progression) were also analyzed using the same 
method as that for OS. The best tumor response rates were 
compared between WBRT plus veliparib 50 mg BID and 
WBRT plus placebo BID, as well as between WBRT plus 
veliparib 200 mg BID and WBRT plus placebo BID treat-
ment groups using the Cochran–Mantel–Haenszel test strati-
fied by GPA score (≤2.5 versus >2.5). Additional analyses 
Baseline neurologic assessme t, Q L evaluation ,
and activities of daily living assessments were p rformed 
≤7 days before randomization. Patients were randomized 
1:1:1 to WBRT plus veliparib BID (50 or 200 mg) or pla-
cebo BID (Fig. 1 ). Patients were stratified by graded prog-
nostic assessment (GPA) score (≤2.5 versus >2.5) and
neurologic symptoms (symptomatic versus asymptomatic). 
The treatment period began on the first day of WBRT and 
continued for 45 days. The follow-up period then consisted 
of patient visits that included QoL measurements, assess-
ment of vital signs and KPS scales, clinical laborat ry test, 
physical and neurologic examinations, and MRIs which 
continued for 3 years or until time of death, whichever was 
first. Treatment was required to begin within 28 days of the 
diagnosis of brain metastases. All patients received 30.0 Gy 
of WBRT in ten daily fractions of 3.0 Gy, given 5 days p r 
week (excluding holidays and weekends). Oral veliparib 
BID (50 or 200mg) or placebo BID was self-administered 
starting on day 1 of WBRT and continued until 1 day afte  
completion of WBRT, including weekends and holidays.
Study visits and procedures during the treatment period 
were performed on treatment days 1, 8, and the last day 
of treatment with WBRT. During the trea ment pe od, if 
a patient discontinued veliparib/placebo and WBRT du  to 
both radiographic and clinical brain metastases progression, 
the patient continued to be foll wed for survival and post-
treatment therapy data for up to 36 months.
During the follow-up period, study visits and safety 
assessments (physical examinations, vital sign , KPS, and 
laboratory tests), radiographic assessments (brain MRIs) and
neurologic assessments (standardized clinical neurologic 
examination, physician inventory of neurologic symptoms, 
Fig. 1 Study design. BID twice 
daily, ITT intent to treat, NSCLC 
non-small cell lung cancer, 
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There was no significant difference in OS between either 
of the WBRT plus veliparib (50 or 200 mg) arms and the 
WBRT plus placebo arm (Fig. 2 ).
OS was also evaluated for the following subgroups: GPA 
score, sex, age, geographic region, presence of extracranial 
metastases, number of brain metastases, baseline KPS, smok-
ing status, asymptomatic/symptomatic neurologic impairment, 
neurologic and psychiatric history, and race. No significant dif-
ference in OS was detected amongst the different subgroups 
analyzed (Fig. 2). Investigator assessment of epidermal growth 
factor receptor (EGFR) mutations and anaplastic lymphoma 
kinase (ALK) rearrangements were collected; however, they 
were infrequently reported. Therefore, it was not possible to 
draw conclusions with the very limited numbers.
Evaluation of secondary endpoints (best tumor response 
rate, time to clinical brain metastases progression, and time 
to intracranial radiographic progression), also did not iden-
tify any significant differences between either of the velipa-
rib (50 mg versus 200 mg) plus WBRT arms and the placebo 
plus WBRT arm (Table2). Eighty-seven patients (33, 29, 
and 25) had radiographic progression found in either tar-
get lesions or new lesions; 41 (18, 12, and 11) had new 
lesions and 58 (18, 21, and 19) had progression of target 
lesions. The best tumor response rate (complete and partial 
responses) was also similar between the arms, at 41.2, 36.9, 
and 42.2 %  See Table 2  for full efficacy results. Addition-
ally, there was no difference in change from baseline in neu-
rocognitive tests measured by z-score across all scheduled 
visits between either veliparib dose groups (50 mg versus 
200 mg) and placebo group.
Safety
The majority of patients in all treatment arms experienced at 
least one AE (any grade) within 30 days that was deemed to 
be related to the study drug or WBRT. The most common 
(≥10 % of patients) treatment-emergent AEs, Grade 3/4 AEs 
(≥3 % of patients), and statistically significant AEs are listed 
in Table 3. Across all three arms the most common AEs were 
nausea (30, 22, 31 %), fatigue (22, 26, 21 %), alopecia (19, 
15, 15 %), and headache (15, 18, 21 %). Pneumonia (6, 3, 
2  %) and fatigue (4, 2, 2 %) were the most frequently reported 
Grade 3/4 AEs considered possibly related to study drug. 
There was a lower incidence for Grade 3/4 AEs in the veli-
parib arms (50 mg versus 200 mg; p< 0.05) compared with 
placebo. No new safety signals of veliparib were identified.
Discussion
This phase 2, randomized study evaluated the efficacy and 
safety of veliparib administered during WBRT for patients 
with brain metastases from NSCLC. Although preclinical 
were performed using a Cox proportio al hazards model to 
explore the effect of baseline factors, including GPA sc e, 
neurologic symptoms, sex, age, region, and thers.
Safety evaluations included the assessment of treatment-
emergent adverse events (AEs) (e.g. those that had an onset 
on or after the first day of the first dose of study drug) through-
out the study using the National Cancer In titute Common 
Terminology Criteria for Adverse Events (version 4.0). AEs
were reported up to 30 days after completion of velip rib 
and placebo. After 30 days, investigators were requ ed  
report any significant AEs (Grade 3/4) and/or serious AEs 
considered to be related to treatment. Patients who received 
≥1 dose were included in the safety analys s. Fish r’s exact 
test was performed to compare the percentages of patients 
experiencing an AE between WBRT plus placebo BID ver-
sus WBRT plus veliparib BID (50 or 200 mg).
Results
Baseline characteristics
In total, 307 patients were randomly assigned to WBRT plus 
placebo BID (n = 102), WBRT plus 50 mg veliparib BID 
(n = 103) and WBRT plus 200 mg veliparib BID (n = 102). 
There was only one patient who was lost t  follow-up f r 
survival information, see the CONSORT diagram (Fig. 1 ). 
Baseline characteristics of the patients were g nerally well 
balanced among the treatment groups (Tabl 1 ). The median 
age (and range) of the treatment grou s was 60 (41–86), 
60 (33–83), and 62 (39–81) years, and 55, 59, and 65 % of
patients were males, respectiv l . The most common sub-
type of NSCLC at diagnosis was adenocarcinoma (WBRT 
plus placebo BID, 80 %; WBRT plus 50 mg veliparib BID, 
83 % and WBRT plus 200 mg veliparib BID, 75 %). The 
majority of patients had GPA scores ≤2.5 (89, 88, and 90 %,
respectively) and KPS > 80 (61, 66, and 62 %, respectively).
Study drug exposure
Study drug and WBRT exposure was similar across treat-
ment arms; no statistical differences wer  observed between 
arms and all patients received the recommended study dose 
(Supplemental Table 1). Pharmacokinetic results confirmed 
drug levels for veliparib and no measurable drug exposures 
for those on placebo (data not shown).
Efficacy
The median OS was 185 d ys for patients treated with 
WBRT plus placebo, 209 days for WBR  plus 50 mg veli-
parib (p = 0.927 versus placebo), and 209 days for WBRT 
plus 200 mg veliparib (p = 0.905 versus placebo; Ta le 2 ). 
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Placebo + WBRT ( N = 102) Veliparib  
50 mg + WBRT  
(N = 103)
Veliparib 
200 mg + WBRT 
(N = 102)
Age, median (range) 60 (41–86) 60 (33–83) 62 (39–81)
Sex, n (%)
Male 56 (55) 61 (59) 66 (65)
Female 46 (45) 42 (41) 36 (35)
Race, n (%)
White 79 (78) 85 (83) 66 (65)
African American 0 (0) 2 (2) 6 (6)
Asian 22 (22) 16 (16) 28 (28)
Region, n (%)a
USA 15 (15) 12 (12) 9 (9)
Non-USA 87 (85) 91 (88) 93(91)
Histology at diagnosis, n (%)
Adenocarcinoma 81 (80) 86 (83) 77 (75)
Squamous cell carcinoma 11 (11) 13 (13) 17 (17)
Large cell carcinoma 7 (7) 0 (0) 5 (5)
Other 2 (2) 4 (4) 3 (3)
Missing 1 0 0
GPA score, n (%)
≤2.5 91(89) 91 (88) 92 (90)
>2.5 11 (11) 12 (12) 10 (10)
Neurological symptoms (IVRS/IWR), n (%)
Asymptomatic 53 (52) 53 (52) 53 (52)
Symptomatic 59 (58) 50 (49) 49 (48)
KPS, n (%)
≤80 39 (39) 35 (34) 39 (38)
>80 62 (61) 68 (66) 63 (62)
Missing 1 0 0
Number of brain mets (per central review), n (%)
1 18 (18) 22 (22) 14 (14)
2–3 22 (22) 26 (26) 29 (19)
>3 58 (59) 53 (51) 56 (57)
Unknown/missing 4 2 3
Extracranial mets, n (%)
Yes 68 (67) 76 (74) 74 (73)
No 33 (32) 27 (26) 28 (27)
Unknown 1 0 0
Smoking, n (%)b
Current 25 (25) 22 (21) 20 (20)
Former 52 (51) 63 (61) 58 (57)
Never 24 (47) 18 (17) 23 (23)
EGFR, n (%)c
No 34 (64) 35 (71) 35 (66)
Yes 19 (36) 14 (29) 18 (34)
Unknown 48 53 49
Missing 1 1 0
ALK, n (%)c
No 26 (100) 24 (96) 27 (96)
Table 1 Patient demographics and baseline characteristics
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is a part of contemporary guidelines. In addition, the role 
of WBRT continues to be evaluated in a number of clini-
cal trials including the NRG (National Surgical Adjuvant 
Breast and Bowel Project, Radiation Therapy Oncology 
Group, and Gynecologic Oncology Group), which has two 
phase 3 trials (NRG-CC001 and NRG-CC003) evaluating 
the role of WBRT versus hippocampal avoidance (HA) 
WBRT [ 28 ]. These trials will test whether HA-WBRT 
decreases the risk for neurocognitive decline in patients 
undergoing WBRT and underscores the ongoing need to 
assess WBRT in the population of NSCLC patients with 
brain metastases.
Historically, randomized trials evaluating novel treat-
ment options for patients with brain metastases have 
included a heterogeneous population of primary tumors [29 , 
30]. Typically, the mixture of primary tumors in these tri-
als includes 50 % NSCLC, 15–20 % breast cancer, 15–20 % 
melanoma, and a few other tumor types [13]. The prognosis 
of patients and their response to local or systemic treatment 
differs amongst primary tumor types as well as histologic 
groups. The heterogeneity within trials, in addition to small 
patient numbers reported in historic trials, has complicated 
and early clinical data sugge ted that veliparib might pot n-
tiate the efficacy of radiotherapy, no difference was observed 
in the assessed endpoints between WBRT combine  with 
veliparib (50 or 200 mg) or placebo. Safety p rameters dem-
onstrated an AE profile similar to the placebo arm, with no 
new safety signals of veliparib identified. The phase 1 trial 
examining combination therapy with veliparib and WBRT 
in patients with brain metastases suggested that this herapy 
would be beneficial for this poor prognosis patient popula-
tion. This finding was not validated within this phase 2 trial. 
Although the primary endpoint of the current study was not 
met, the results of the study m y provide additional infor-
mation that will prove valuable for the design of future trials 
involving patients with brain metas ase  rom NSCLC.
In the reported trial, patients were de m d suitable can-
didates for WBRT based upon the judgement of the indi-
vidual investigator. This decis on took into account not 
only the number, size, and location of the metastas s, but 
also the systemic tumor burden and other fac ors that w uld 
favor the use of WBRT over other therapeutic options (eg, 
SRS). From a global perspective, WBRT remains th  most 
common standard of care for patients with this disease and 
Table 2 Summary of primary and secondary endpoints
Placebo +  WBRT 
(N = 102)a
Veliparib 50 mg + WBRT 
(N = 103) 
Veliparib 200 mg + WBRT 
(N = 102)
Median overall survival, days (95 % CI) 185 (137, 251) 209 (169, 264) p = 0.933 209 (138, 255) p = 0.909
Objective response rate, (%) 41.2 36.9 p = 0.535 42.2 p = 0.898
Median time to clinical brain metastasis progressiona,  
days (95 % CI)
348 (216, NR) 286 (192, NR) p = 0.864 255 (204, 342)p = 0.301
Median time to radiographic brain metastasis progressionb, 
days (95 % CI)
259 (184, NR) 226 (147, 360) p = 0.314 224 (137, 358) p = 0.536
p values (against placebo)
CI confidence interval, NR not reached, WBRT whole-brain radiation therapy
aPer event review board
bPer central imaging center
Placebo + WBRT ( N = 102) Veliparib  
50 mg + WBRT  
(N = 103)
Veliparib 
200 mg + WBRT 
(N = 102)
Yes 0 (0) 1 (4) 1 (4)
Unknown 75 77 74
Missing 1 1 0
Percentages based on known data
ALK anaplastic lymphoma kinase, EGFR epiderm l growth factor receptor, GPA graded prognostic assessment, IVRS/IWR, interactive voice/
web response system, KPS Karnofsky performance status, mets etastases, WBRT whole-brain radiation therapy
aOne patient in placebo arm is Native Hawaiian or Pacific islander
bMissing smoking status for one patient in placebo arm
cEGFR and ALK status was not required and the majority of sites did not report; percentages based on known data
Table 1 (continued) 
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Fig. 2 Overall survival—all randomized patients and subgroup analysis. GPA gr ded prog ostic assessment, KPS Karn fsky performance score, 
mets, metastases, neruo n urologic, PSY psychologic, WBRT whole-brain radiation therapy
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patients with GPA score >2.5 (HR 0.68, 95 % confidence 
interval [95 % CI] 0.24–1.91 and HR 0.65, 95 % CI 0.22–
1.94) in comparison to patients with GPA score ≤ 2.5 (HR 
1.03, 95 % CI 0.73–1.44 and HR 1.02, 95 % CI 0.73–1.36) 
with both 50 or 200 mg doses of veliparib, respectively is 
noteworthy (Fig. 2 ). However, this data should be inter-
preted with caution due to the limited number of patients 
with GPA score >2.5 (n = 11) in comparison to patients 
with GPA scores ≤2.5 (n = 91). Nevertheless, the benefit of 
the identification of prognostic factors as well as the devel-
opment of better treatments and methods to assess outcomes 
[29 , 30].
In addition to heterogeneity in patient populations, 
responses have been inconsistently evaluated, making it 
challenging to compare findings across trials. The major-
ity of trials have either used response criteria developed 
for solid tumors (e.g. RECIST [26 , 27] or World Health 
Organization [31 ]) or modified versions of response crite-
ria developed specifically for high-grade gliomas (Macdon-
ald criteria [25], Response Assessment in Neuro-Oncology 
[RANO] [32]). Objective response assessment remains a 
common endpoint in phase 2 trials in patients with brain 
metastases given the likelihood for regulatory approval of 
the respective drug and or therapeutic regimen if response 
rates are favorable [33, 34].
The RANO working group recently developed recom-
mendations to improve the design and implementation of 
clinical trials in patients with brain metastases [29 , 30]. 
One of the consensus recommendations involved limiting 
the patient population of trials evaluating systemic treat-
ments to a specific primary tumor type (or primary tumor 
subtype, if applicable). RANO also recommended that trials 
archive imaging studies with linked outcomes data to allow 
retrospective analyses comparing measurement techniques, 
response criteria, and associations with neurologic and sur-
vival outcomes [29 ].
This study was a randomized trial involving a relatively 
homogeneous population of patients with brain metastases 
from NSCLC. The majority of patients across all treatment 
groups had GPA scores ≤2.5 (88–90 %) and KPS > 80 (61–
66 %). OS was not significantly different between WBRT 
plus either dose of veliparib (50 and 200 mg; 185 days each)
or placebo (209 days). OS was also similar to estimated 
disease-specific GPA for patients with NSCLC and brain 
metastases [35]. The reported patient demographics and 
survival results are comparable with previously published 
data indicating the treated population was not atypical [23, 
36]. Unfortunately, we did not have EGFR mutations and 
ALK rearrangements data for many patients, which greatly 
limited our ability to analyze the impact of EGFR and ALK 
on outcomes.
Recently a secondary analysis of a randomized trial com-
paring SRS alone to WBRT plus SRS in patients with brain 
metastases from NSCLC has been reported [37]. From a 
survival standpoint, patients with a favorable prognosis (eg, 
GPA score 2.5–4) had a significantly longer median survival 
with WBRT plus SRS (16.7 months) when compared to SRS 
alone (10.6 months; p = 0.04). This benefit was not observed 
in the unfavorable prognosis group (eg, GPA score <2.5; 
p = 0.86). Although there was not a s atistical therapeutic 
advantage between WBRT plus either do e f veliparib or 
placebo in the reported trial, hazard ratio (HR) analyses in 
Table 3 Summary of adverse events
Placebo + WBRT 
(N = 101)a
Veliparib 
50 mg + WBRT 
(N = 103)
Veliparib 
200 mg + 
WBRT  
(N = 102)
Any AE, n (%) 91 (90) 90 (87) 90 (98)
Any g ade 3/4, n (%)43 (43) 29 (28)b 26 (25)b
Any SAE, n (%) 39 (39) 31 (30) 36 (35)
Any fatal AE, n (%)13 13 11 (11) 18 (18)
Any AE (≥10 % patients), n (%)
Naus a 30 (30) 23 (22) 32 (31)
Fatigue 22 (22) 27 (26) 21 (21)
Alopec a 19 (19) 15 (15) 15 (15)
Headache 15 (15) 18 (17) 21 (21)
D creased appetite14 (14) 11 (11) 15 (15)
Dyspnea 14 (14) 8 (8) 11 (11)
Constipation12 (12) 10 (10) 11 (11)
Insomnia 11 (11) 10 (10) 6 (6)
Asthenia 11 (11) 9 (9) 13 (13)
Dizziness 11 (11) 8 (8) 10 (10)
Malignant neoplasm 
progression
8 (8) 11 (11) 18 (18)
Any G ade 3/4 AE (≥3% pati nts), n (%)
Pneumonia 6 (8) 3 (3) 2 (2)
Fat gue 4 (4) 2 (2) 2 (2)
P in 4 (4) 1 (1) 0 (0)
Anemia 3 (3) 1 (1) 2 (2)
Dehydration3 (3) 0 (0) 1 (1)
Brain edema 3 (3) 0 (0) 0 (0)
Convulsion 3 (3) 0 (0) 0 (0)
Malignant neoplasm 
progression
2 (2) 2 (2) 4 (4)
Pulmonary embolism1 (1) 4 (4) 2 (2)
Thrombocytopenia1 (1) 3 (3) 2 (2)
Hyperglycemia1 (1) 2 (2) 3 (3)
Statistically significant AEs, n (%)
Vomiting 15 (15) 5 (5)b 11 (11)
Brain edema 6 (6) 1 (1) 0 (0)b
Dehydration5 (5) 0 (0)b 1 (1)
AE adverse event, SAE s rious adve se event, WBRT whole-brain 
radiation therapy
aSafety analysis population = 101
bp < 0.05
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